Protalix BioTherapeutics, Inc.
- Last sale
- Nov 12, 2026 · -5.90%
- Market cap
- $248.74M
- 84.32M shares
- Filings
- 974
Q3 2026−1.2% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−25.7% FY25 yoy
- $248.74M
- 12.1×
- 2.9×
- 3.1×
- 6.06%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $52,744,000 | reported | |
| FY 2024 | 2024-12-31 | $53,399,000 | reported | |
| FY 2023 | 2023-12-31 | $65,494,000 | reported | |
| FY 2022 | 2022-12-31 | $47,638,000 | reported | |
| FY 2021 | 2021-12-31 | $38,350,000 | reported | |
| FY 2020 | 2020-12-31 | $62,898,000 | reported | |
| FY 2019 | 2019-12-31 | $54,693,000 | reported | |
| FY 2018 | 2018-12-31 | $34,240,000 | reported | |
| FY 2017 | 2017-12-31 | $21,078,000 revised | reported | |
| FY 2016 | 2016-12-31 | $9,199,000 | reported | |
| FY 2015 | 2015-12-31 | $4,364,000 | reported | |
| FY 2014 | 2014-12-31 | $3,523,000 revised | reported |
Segments
Products
LineFY2025ShareChange
GOODS$51.80M98%−2.2%
LICENSE AND R&D SERVICES$942.00K1.8%+125.4%
Total$52.74M
Biological products, except diagnostic substances
Protalix BioTherapeutics, Inc. is the 42nd largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
VIRVir Biotechnology, Inc.$68.6M7.6%638.9%$2.1BCSBRChampions Oncology, Inc.$59.4M4.4%2.0%$76.4MIVVDInvivyd, Inc.$53.4M110.5%98.2%$165.9M
PLXProtalix BioTherapeutics, Inc. (this company)$52.7M1.2%12.5%$248.7M
BSEMBioStem Technologies, Inc.$47.5M31.8%13.9%$24.7MFENCFennec Pharmaceuticals Inc.$44.6M6.1%21.8%$381.4MCHRSCoherus Oncology, Inc.$42.2M59.8%398.4%$83.4MEDITEditas Medicine, Inc.$40.5M25.4%395.0%$329.5MVYGRVoyager Therapeutics, Inc.$40.4M49.5%296.5%$105.8MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR